Royal Bank of Canada (RBC) is telling investors to look past Ideaya Biosciences' well-known uveal melanoma drug and focus on two earlier-stage cancer programs. According to the bank, the company's next big value driver is its PRMT5 and MAT2A pipeline, especially after a recent collaboration with Swiss pharma giant Roche added between $600 million and $1.2 billion to Ideaya's market value.
What's behind the shift?
Ideaya Biosciences, a clinical-stage biotech company, has long been associated with its lead drug candidate for uveal melanoma, a rare cancer of the eye. That drug has been the centerpiece of the company's story for years. But RBC's note suggests that the market's attention is now turning to two other programs: PRMT5 and MAT2A.
PRMT5 and MAT2A are both targets in cancer biology. PRMT5 is an enzyme that helps regulate gene expression, and it's been linked to certain types of tumors. MAT2A is involved in a metabolic pathway that some cancer cells rely on to grow. Both are considered promising areas for new cancer treatments, though they are still in earlier stages of development compared to the melanoma drug.
The catalyst for this shift appears to be the Roche collaboration. While the exact terms of the deal weren't detailed in the brief, RBC estimates that the partnership added $600 million to $1.2 billion in market value to Ideaya. That's a significant boost for a company of its size, and it signals that big pharma sees value in Ideaya's broader pipeline, not just its melanoma asset.
Why investors are paying attention
For everyday investors, the key takeaway is that Ideaya's future growth may no longer hinge on a single drug. Diversifying into multiple cancer programs can reduce risk, but it also means the company's valuation will be tied to the success of earlier-stage science, which is inherently more uncertain.
RBC's note is a reminder that biotech stocks often move on pipeline news, not just on sales of existing products. When a large partner like Roche comes in, it can validate the science and provide much-needed capital. But it also means that the market will be watching for data readouts from the PRMT5 and MAT2A programs, which could be years away from any potential approval.
Investors should also consider the broader context. The biotech sector has been volatile, with interest rates and Treasury yields influencing how much risk investors are willing to take on. Higher yields tend to make future cash flows less attractive, which can weigh on biotech valuations. That's why a partnership like the one with Roche can be so important—it provides near-term cash and reduces some of the risk.
What it means for your portfolio
If you own Ideaya shares, or are considering them, the RBC note suggests that the market's focus is shifting. The melanoma drug is still important, but the PRMT5 and MAT2A programs could be what drives the stock from here. That means you should be prepared for more volatility as clinical data comes out.
For those who don't own the stock, this is a case study in how biotech investing works. It's not just about the drugs on the market today; it's about the pipeline and the partnerships that can unlock value. The Roche deal is a positive signal, but it's not a guarantee of success. Early-stage cancer programs often fail, and even successful ones take years to reach patients.
RBC's view is that the market is starting to price in the potential of these earlier-stage programs. That could mean the stock has already moved on this news, so the easy gains may be behind it. But it also suggests that the company's future is less dependent on a single drug, which could be a positive for long-term investors.
Looking ahead
Investors will likely be watching for updates on the PRMT5 and MAT2A programs, including any early clinical data. They'll also be keeping an eye on how the Roche collaboration progresses, as that could provide additional milestones and payments.
In the meantime, the broader market is also dealing with a busy earnings season and questions about the economy. As tech leads futures higher and investors brace for a heavy earnings week, biotech stocks like Ideaya can be influenced by overall market sentiment. But for now, the story is about the pipeline, not the melanoma drug.
RBC's note is a useful reminder that in biotech, the next big thing is often not the current product. It's the science that's still in the lab. For Ideaya, that science is now front and center.
